SCHEMBL15918007

SCHEMBL15918007

NC(=O)C(N)S(=O)(=O)c1ccccc1Br

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 5/20 0.52
CA1 P00915 4/20 0.52
CA4 P22748 2/20 0.52
CA6 P23280 2/20 0.52
PLCG1 P19174 1/20 0.44
LOX P28300 1/20 0.40
POLB P06746 2/20 0.37
MAPT P10636 1/20 0.36
RECQL P46063 1/20 0.35
CA9 Q16790 4/20 0.35
KYNU Q16719 2/20 0.35
KMT2A Q03164 1/20 0.34
CA12 O43570 2/20 0.34
CA5A P35218 2/20 0.34
CA7 P43166 2/20 0.34
CYP2C9 P11712 1/20 0.34
CA14 Q9ULX7 1/20 0.34
CA5B Q9Y2D0 1/20 0.34
AKR1B1 P15121 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4432528 0.72 CA1 (0.52) CA2CA1CA4CA6PLCG1
SCHEMBL29557979 0.71 CA1 (0.56) CA2CA1CA4CA6PLCG1
SCHEMBL1800130 0.71 CA1 (0.56) CA2CA1CA4CA6PLCG1
SCHEMBL9732632 0.71 CA1 (0.56) CA2CA1CA4CA6PLCG1
SCHEMBL15932404 0.70 POLB (0.51) CA2CA1CA4CA6PLCG1
SCHEMBL6916920 0.70 CA1 (0.60) CA2CA1CA4CA6PLCG1
SCHEMBL30630011 0.69 CA2 (1.00) CA2CA1CA4CA6PLCG1
SCHEMBL344271 0.69 CA2 (1.00) CA2CA1CA4CA6PLCG1
SCHEMBL11226379 0.69 PLCG1 (0.60) CA2CA1CA4CA6PLCG1
SCHEMBL28859539 0.69 CA1 (0.53) CA2CA1CA4CA6PLCG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3495359-A1 FLAP MODULATORS Janssen Pharmaceutica NV (BE) 2019-06-12 EP disclosed
EP-3070085-B1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-01-09 EP disclosed
US-9884878-B2 FLAP modulators JANSSEN PHARMACEUTICA NV (BE) 2018-02-06 US disclosed
EP-3070085-A1 FLAP MODULATORS Janssen Pharmaceutica N.V. (BE) 2016-09-21 EP disclosed
US-20150259357-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2015-09-17 US disclosed
US-9079866-B2 Flap modulators JANSSEN PHARMACEUTICA NV (BE) 2015-07-14 US disclosed
US-20140221311-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (US) 2014-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259357-A1 FLAP MODULATORS PGF, FEN1, TBXA2R CA2 4111/4885CA1 3615/4885CA4 2675/4885
US-20140221311-A1 FLAP MODULATORS PGF, FEN1, TBXA2R CA2 4111/4885CA1 3615/4885CA4 2675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.